Pharsight

1. Ermeza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345772	MYLAN	Liquid levothyroxine formulations	Feb, 2035 (11 years from now)

Market Authorisation Date: 29 April, 2022

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
150MCG/5ML	SOLUTION;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747	MYLAN	Pharmaceutical foam	Jan, 2024 (3 months from now)
US7141237	MYLAN	Pharmaceutical foam	Feb, 2024 (4 months from now)

Market Authorisation Date: 22 October, 2004

Treatment: Treatment of acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.01		1	31 Mar, 2010	09 Aug, 2026	Eligible

Strength	Dosage	Availability
1%	AEROSOL, FOAM;TOPICAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP05775966A	2014-05-14	Henkel AG & Co. KGaA	Patent maintained as amended
EP05775966A	2014-05-14	Generics [UK] Limited	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962000	MYLAN	Microemulsion and sub-micron emulsion process and compositions	Aug, 2025 (1 year, 11 months from now)
US8460641	MYLAN	Microemulsion process and composition	Nov, 2028 (5 years from now)

Market Authorisation Date: 12 January, 2007

Treatment: Treatment of corticosteroid-responsive dermatoses

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	25 Feb, 2010	1	14 Aug, 2012	08 Sep, 2019	Eligible

Strength	Dosage	Availability
0.05%	AEROSOL, FOAM;TOPICAL	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8147852	November, 2010	Decision	Marcel Borgers et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147852	MYLAN	Modified azole compounds as antifungal and antibacterial agents	Mar, 2028 (4 years from now)